Timothy Iveson

Timothy Iveson

UNVERIFIED PROFILE

Are you Timothy Iveson?   Register this Author

Register author
Timothy Iveson

Timothy Iveson

Publications by authors named "Timothy Iveson"

Are you Timothy Iveson?   Register this Author

13Publications

443Reads

15Profile Views

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Nat Commun 2019 05 14;10(1):2154. Epub 2019 May 14.

Colon Cancer Genetics Group, Medical Research Council Human Genetics Unit, Institute of Genetics and Molecular Medicine, Western General Hospital, University of Edinburgh, Edinburgh, EH4 2XU, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-019-09775-w
Publisher Site
http://dx.doi.org/10.1038/s41467-019-09775-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6517433PMC
May 2019

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

N Engl J Med 2018 Mar;378(13):1177-1188

From the Divisions of Medical Oncology (A.G.) and Biomedical Statistics and Informatics (Q.S., J.P.M., L.A.R., D.J.S.), Mayo Clinic, Rochester, MN; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Martino-IST, Genoa (A.F. Sobrero), Ospedale Papa Giovanni XXIII, Bergamo (R.L.), and IRCCS Mario Negri Institute for Pharmacological Research, Milan (V.T.) - all in Italy; Karmanos Cancer Institute, Wayne State University, Detroit (A.F. Shields); National Cancer Center Hospital East, Chiba (T. Yoshino), Yokohama City University School of Medicine, Yokohama (T. Yamanaka), and the University of Tokyo, Tokyo (T.W.) - all in Japan; the Institute of Cancer Sciences, University of Glasgow, Glasgow (J.P.), the University of Oxford, Oxford (R.K.), Christie Hospital, Manchester (M.S.), and University Hospital Southampton, Southampton (T.I.) - all in the United Kingdom; Hôpital Européen Georges-Pompidou, Sorbonne Paris Cite/Paris Descartes University (J.T.), and Saint-Antoine Hospital and Sorbonne Universités, Pierre and Marie Curie University-Paris 6 (T.A.), Paris, and Methodology and Quality of Life Unit, INSERM Unité 1098, Besançon (D.V.) - all in France; the Department of Medical Oncology, University Hospital of Heraklion, Faculty of Medicine, University of Crete, Heraklion (J.S.), and Bioclinic Thessaloniki, Thessaloniki (I.B.) - both in Greece; Dana-Farber Cancer Institute, Boston (J.A.M.); and Duke Cancer Institute, Durham, NC (D.N.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1713709DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426127PMC
March 2018

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.

World J Gastrointest Oncol 2017 Aug;9(8):333-340

Michael Davidson, Ian Chau, David Cunningham, Komel Khabra, Naureen Starling, Royal Marsden Hospital NHS Foundation Trust, London and Surrey, London SM25PT, United Kingdom.

View Article

Download full-text PDF

Source
http://www.wjgnet.com/1948-5204/full/v9/i8/333.htm
Publisher Site
http://dx.doi.org/10.4251/wjgo.v9.i8.333DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561045PMC
August 2017

Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.

World J Gastroenterol 2013 Dec;19(48):9282-93

Fergus Noble, Luke Nolan, Tim J Underwood, Andrew R Bateman, Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v19.i48.9282DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882401PMC
December 2013

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

N Engl J Med 2008 Jan;358(1):36-46

Royal Marsden Hospital National Health Service Foundation Trust, Surrey and London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa073149DOI Listing
January 2008